We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
Read MoreHide Full Article
Key Takeaways
OMER secured FDA approval for YARTEMLEA to treat TA-TMA in adults and pediatric patients aged two and older.
OMER showed strong results, with complete responses up to 68% and improved 100-day survival in studies.
OMER's first commercial product is set to generate revenues, with U.S. delivery planned for January 2026.
Omeros Corporation (OMER - Free Report) recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent life-threatening condition that can occur after stem cell transplants. YARTEMLEA is approved for adults and pediatric patients aged two years and older and is the first and only therapy indicated for TA-TMA.
YARTEMLEA works by blocking MASP-2, the key enzyme of the lectin complement pathway, preventing pathway activation while keeping other important immune defense pathways intact. The approval was supported by a single-arm clinical study on 28 adult patients and an expanded access program that included 221 adult and pediatric patients, both enrolling high-risk TA-TMA patients.
Per management, the FDA approval of YARTEMLEA is a major achievement for the company and a significant step forward for patients and families affected by TA-TMA. After years of work with the transplant community, OMER is committed to delivering YARTEMLEA, the first FDA-approved treatment for this fatal condition, supported by strong clinical results and a favorable safety profile for both adults and children in the United States in January 2026.
OMER Stock Trend Following the News
Shares of Omeros have gained 2.3% since the announcement on Wednesday. Over the past six months, shares of the company have skyrocketed 423.7% compared with the industry’s 1.3% growth and the S&P 500’s 14.5% rise.
Image Source: Zacks Investment Research
In the long run, FDA approval of YARTEMLEA represents a transformative milestone for Omeros as its first commercial product, shifting the company from a development-stage to a revenue-generating organization. A successful launch in the United States, and potentially in Europe, combined with the reimbursement codes already in place, would provide OMER with steady revenues, a platform for potential expansion and further strengthen its position as a commercial biotechnology company.
OMER currently has a market capitalization of $1.11 billion.
More on YARTEMLEA Approval
In the TA-TMA study, among patients treated with YARTEMLEA, 61% showed a complete response, meaning better lab results along with improved organ function or no longer needing transfusions. In the expanded access program, the complete response reached 68%. YARTEMLEA treatment was associated with an improved survival rate in high-risk TA-TMA patients. About 73% of patients in the main study and 74% in the expanded access program were alive 100 days after diagnosis, a significant improvement in historical outcomes in high-risk TA-TMA.
As the first approved treatment for TA-TMA, YARTEMLEA represents a life-saving standard treatment for children aged two and older undergoing stem cell transplants. The clinical data show that Narsoplimab provides strong response rates and better survival, with an acceptable safety profile. The company has already secured the necessary billing and reimbursement codes. These include a specific diagnosis code for TA-TMA and procedure codes that cover how YARTEMLEA is given through either a peripheral or central vein.
The approval of YARTEMLEA strengthens OMER’s position in the biotech and rare-disease sector. It establishes the company as a leader in the treatment of TA-TMA, a life-threatening condition of stem cell transplants, giving the company a first-mover advantage in the critical orphan indications market. With a European regulatory decision expected in mid-2026, OMER aims to gain market visibility and strengthen its longer-term pipeline credibility by validating its complement-pathway expertise.
Industry Prospects Favoring the Stem Cell Therapy Market
Going by data provided by Precedence Research, the stem cell therapy market is valued at $6.75 billion in 2025 and is expected to witness a CAGR of 12.6% through 2034. Factors like the rising incidence of chronic illnesses like cancer, diabetes and neurological problems, along with the poor effectiveness of current treatments, fuel the need for alternative remedies and drive the market’s growth.
Other News
Omeros announced that it has completed the sale and licensing deal with Novo Nordisk for its drug candidate zaltenibart (OMS906). Zaltenibart is a late-stage, first-in-class antibody that targets MASP-3, a key activator of the complement system and offers advantages over other similar drugs in development or on the market.
The company has formed an Oncology Clinical Steering Committee to guide its OncotoX program for acute myeloid leukemia. The program uses specially designed, small molecules that deliver toxic payloads directly into cancer cells, aiming to kill them and address a major unmet medical need.
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , AtriCure (ATRC - Free Report) and Boston Scientific (BSX - Free Report) .
Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
AtriCure, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted loss per share of 1 cent, narrower than the Zacks Consensus Estimate by 90.9%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 11.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.9% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
Key Takeaways
Omeros Corporation (OMER - Free Report) recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent life-threatening condition that can occur after stem cell transplants. YARTEMLEA is approved for adults and pediatric patients aged two years and older and is the first and only therapy indicated for TA-TMA.
YARTEMLEA works by blocking MASP-2, the key enzyme of the lectin complement pathway, preventing pathway activation while keeping other important immune defense pathways intact. The approval was supported by a single-arm clinical study on 28 adult patients and an expanded access program that included 221 adult and pediatric patients, both enrolling high-risk TA-TMA patients.
Per management, the FDA approval of YARTEMLEA is a major achievement for the company and a significant step forward for patients and families affected by TA-TMA. After years of work with the transplant community, OMER is committed to delivering YARTEMLEA, the first FDA-approved treatment for this fatal condition, supported by strong clinical results and a favorable safety profile for both adults and children in the United States in January 2026.
OMER Stock Trend Following the News
Shares of Omeros have gained 2.3% since the announcement on Wednesday. Over the past six months, shares of the company have skyrocketed 423.7% compared with the industry’s 1.3% growth and the S&P 500’s 14.5% rise.
Image Source: Zacks Investment Research
In the long run, FDA approval of YARTEMLEA represents a transformative milestone for Omeros as its first commercial product, shifting the company from a development-stage to a revenue-generating organization. A successful launch in the United States, and potentially in Europe, combined with the reimbursement codes already in place, would provide OMER with steady revenues, a platform for potential expansion and further strengthen its position as a commercial biotechnology company.
OMER currently has a market capitalization of $1.11 billion.
More on YARTEMLEA Approval
In the TA-TMA study, among patients treated with YARTEMLEA, 61% showed a complete response, meaning better lab results along with improved organ function or no longer needing transfusions. In the expanded access program, the complete response reached 68%. YARTEMLEA treatment was associated with an improved survival rate in high-risk TA-TMA patients. About 73% of patients in the main study and 74% in the expanded access program were alive 100 days after diagnosis, a significant improvement in historical outcomes in high-risk TA-TMA.
As the first approved treatment for TA-TMA, YARTEMLEA represents a life-saving standard treatment for children aged two and older undergoing stem cell transplants. The clinical data show that Narsoplimab provides strong response rates and better survival, with an acceptable safety profile. The company has already secured the necessary billing and reimbursement codes. These include a specific diagnosis code for TA-TMA and procedure codes that cover how YARTEMLEA is given through either a peripheral or central vein.
The approval of YARTEMLEA strengthens OMER’s position in the biotech and rare-disease sector. It establishes the company as a leader in the treatment of TA-TMA, a life-threatening condition of stem cell transplants, giving the company a first-mover advantage in the critical orphan indications market. With a European regulatory decision expected in mid-2026, OMER aims to gain market visibility and strengthen its longer-term pipeline credibility by validating its complement-pathway expertise.
Industry Prospects Favoring the Stem Cell Therapy Market
Going by data provided by Precedence Research, the stem cell therapy market is valued at $6.75 billion in 2025 and is expected to witness a CAGR of 12.6% through 2034. Factors like the rising incidence of chronic illnesses like cancer, diabetes and neurological problems, along with the poor effectiveness of current treatments, fuel the need for alternative remedies and drive the market’s growth.
Other News
Omeros announced that it has completed the sale and licensing deal with Novo Nordisk for its drug candidate zaltenibart (OMS906). Zaltenibart is a late-stage, first-in-class antibody that targets MASP-3, a key activator of the complement system and offers advantages over other similar drugs in development or on the market.
The company has formed an Oncology Clinical Steering Committee to guide its OncotoX program for acute myeloid leukemia. The program uses specially designed, small molecules that deliver toxic payloads directly into cancer cells, aiming to kill them and address a major unmet medical need.
Omeros Corporation Price
Omeros Corporation price | Omeros Corporation Quote
OMER’s Zacks Rank & Other Key Picks
Currently, OMER has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , AtriCure (ATRC - Free Report) and Boston Scientific (BSX - Free Report) .
Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
AtriCure, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted loss per share of 1 cent, narrower than the Zacks Consensus Estimate by 90.9%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 11.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.9% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.